Evidence map›Paper›PMID 19470835›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2009

Epidermal growth factor receptor cross-talks with ligand-occupied estrogen receptor-alpha to modulate both lactotroph proliferation and prolactin gene expression.

Shenglin Chen, Madhavi Latha Yadav Bangaru, Leighton Sneade, Joseph A Dunckley, Nira Ben-Jonathan, Sanjay Kansra

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.The Journal of clinical endocrinology and metabolism · 2021
    Trial
  2. Review
  3. Forskolin Stimulates Estrogen Receptor (ER)International journal of endocrinology · 2022
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shenglin ChenDepartment of Endocrinology, Metabolism and Clinical Nutrition, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Madhavi Latha Yadav Bangaru
Leighton Sneade
Joseph A Dunckley
Nira Ben-Jonathan
Sanjay Kansra
Medical College of Wisconsin · US

Funding

REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY RESEARCHP30ES006096 · NIEHS · UNIVERSITY OF CINCINNATI · PI PINNEY, SUSAN MENGEL · 1992 to 2022
$35.4M
Prolactin as a Growth Factor in Breast CancerR01CA096613 · NCI · UNIVERSITY OF CINCINNATI · PI BEN-JONATHAN, NIRA · 2004 to 2013
$2.7M
Xenoestrogens: Genomic and Non-genomic MechanismsR01ES012212 · NIEHS · UNIVERSITY OF CINCINNATI · PI BEN-JONATHAN, NIRA · 2003 to 2006
$1.1M
NCI NIH HHS BC050725NCI NIH HHS CA096613NIEHS NIH HHS ES012212NIEHS NIH HHS P30-ES06096
6 · The paper itself

Abstract

Both estrogen (E2) and EGF regulate lactotrophs, and we recently demonstrated that EGF phosphorylates S118 on estrogen receptor-alpha (ERalpha) and requires ERalpha to stimulate prolactin (PRL) release. However, the interactions between ligand-occupied ERalpha and activated ErbB1 and its impact on lactotroph function are unknown. Using rat GH3 lactotrophs, we found that both E2 and EGF independently stimulated proliferation and PRL gene expression. Furthermore, their combination resulted in an enhanced stimulatory effect on both cell proliferation and PRL gene expression. Inhibitors of ER as well as ErbB1 blocked the combined effects of E2 and EGF. Pretreatment with UO126 abolished the combined effects, demonstrating Erk1/2 requirement. Although bidirectionality in ER-ErbB1 cross-talk is a well-accepted paradigm, interestingly in lactotrophs, ErbB1 kinase inhibitor failed to block the effect of E2 on proliferation and stimulation of PRL gene expression, suggesting that ER does not require ErbB1 to mediate its effects. Furthermore, E2 did not affect the ability of EGF to induce c-Fos expression or modulate AP-1 activity. However, both E2 and EGF combine to enhance S118 phosphorylation of ERalpha, leading to enhanced E2-mediated estrogen response element transactivation. Taken together, our results suggest that, in lactotrophs, activated ErbB1 phosphorylates ERalpha to enhance the stimulatory effect of E2, thereby providing the molecular basis by which EGF amplifies the response of E2.

Indexed as

Cell ProliferationAnimalsCells, CulturedEpidermal Growth FactorErbB ReceptorsEstradiolEstrogen Receptor alphaEstrogen Receptor betaGene Expression RegulationGenes, fosLactotrophsLigandsProlactinRatsReceptor Cross-TalkResponse ElementsEpidermal Growth FactorErbB ReceptorsEstradiolEstrogen Receptor alphaEstrogen Receptor betaLigandsProlactinTranscription Factor AP-1

Identifiers

PMID19470835
PMCPMC2724110
OpenAlexW2128045645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.